3I1Y

Crystal Structure of soluble epoxide Hydrolase

Summary for 3I1Y

• Entry DOI: 10.2210/pdb3i1y/pdb
• Related: 3I28
• Descriptor: Epoxide hydrolase 2, N-(3,3-diphenylpropyl)pyridine-3-carboxamide (3 entities in total)
• Functional Keywords: hydrolase, aromatic hydrocarbons catabolism, cytoplasm, detoxification, magnesium, metal-binding, peroxisome, polymorphism
• Biological source: Homo sapiens (human)
• Cellular location: Cytoplasm: P34913
• Total number of polymer chains: 1
• Total formula weight: 63002.01

Authors

Farrow, N.A. (deposition date: 2009-06-28, release date: 2009-10-13, Last modification date: 2024-02-21)

Primary citation

Eldrup, A.B.,Soleymanzadeh, F.,Taylor, S.J.,Muegge, I.,Farrow, N.A.,Joseph, D.,McKellop, K.,Man, C.C.,Kukulka, A.,De Lombaert, S.
Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
J.Med.Chem., 52:5880-5895, 2009

PubMed Abstract: Inhibition of soluble epoxide hydrolase (sEH) is hypothesized to lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties. As part of an effort to identify inhibitors of sEH with high and sustained plasma exposure, we recently performed a high throughput screen of our compound collection. The screen identified N-(3,3-diphenyl-propyl)-nicotinamide as a potent inhibitor of sEH. Further profiling of this lead revealed short metabolic half-lives in microsomes and rapid clearance in the rat. Consistent with these observations, the determination of the in vitro metabolic profile of N-(3,3-diphenyl-propyl)-nicotinamide in rat liver microsomes revealed extensive oxidative metabolism and a propensity for metabolite switching. Lead optimization, guided by the analysis of the solid-state costructure of N-(3,3-diphenyl-propyl)-nicotinamide bound to human sEH, led to the identification of a class of potent and selective inhibitors. An inhibitor from this class displayed an attractive in vitro metabolic profile and high and sustained plasma exposure in the rat after oral administration.

PubMed: 19746975
DOI: 10.1021/jm9005302

Experimental method

X-RAY DIFFRACTION (2.469 Å)